Bayer, Novartis, and Trump convicted by NatureThe politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine. more ➔
Drug from worms dampens autoimmune responseGerman researchers have isolated a substance from parasitic roundworm larvae to alleviate inflammation and treat asthma in a rodent model. more ➔
Swiss biotech sector with robust growth Last year, the biotechnology sector in Switzerland has continued its growth and proved to be a magnet for fresh capital and investment. This is revealed by the Swiss Biotech Report 2020. more ➔
COVID-19: Novartis starts study on hyped malaria drugUp to today, Novartis and Bayer announced donations of several millions of old antimalaria pills based on anecdotical reports of efficacy in COVID-19 patients. Now Novartis has started a study. more ➔
COVID 19: Halix ready for vaccine productionDutch Halix BV will manufacture a ChAdOx1 nCoV-19 vaccine, developed at the University of Oxford . more ➔
Carbios SAS publishes PET recycling technologyFor years, French Carbios SAS has worked to set up a process that effectively depolymerizes PET, one of the most common plastics. Now its process has been published. more ➔
Mobidiag’s COVID-19 test okayed for emergency useMolecular diagnostics specialist Mobidiag Ltd has got emergency approval for its Amplidiag® COVID-19 molecular diagnostic test in Finland. more ➔
Researchers reconstruct SARS-CoV-2 evolutionBritish researchers have tabled a phylogenetic tree showing different subtypes of SARS-CoV-2 developed in Asia, Europe and the US. more ➔
COVID-19: Solnatide approved for compassionate useAustrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide. more ➔
GE renamed Cytiva upon take-over by DanaherFollowing the completion of Danaher’s €19.5bn take-over of GE Healthcare Life Sciences, GE’s CDMO arm is renamed Cytiva. more ➔
